Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma

Published:2022-11-01 Issue:21 Volume:61 Page:3157-3164
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sugimoto Rie¹,Motomura Kenta²,Ooho Aritsune³,Aratake Yoshifusa⁴,Ueda Akihiro⁵,Senju Takeshi¹,Tanaka Yuki¹,Yada Masayoshi²,Tanaka Kohsuke²,Kuwano Akifumi²,Morita Yuusuke²,Nagasawa Shigehiro²,Ooe Mari³,Mutsuki Taiji³,Yoshimoto Tsuyoshi⁴,Yamashita Naoki⁴,Nakashima Mai⁴,Hioki Tomonobu⁴,Koyanagi Toshimasa⁵,Higuchi Nobito⁵,Nakamura Tsukasa⁵,Harada Shigeru⁶,Tanaka Masatake⁷,Tada Seiya⁸,Satoh Takeaki⁹,Uchimura Koutarou¹⁰,Kuniyoshi Masami¹¹,Nakamuta Makoto⁴,Kohjima Motoyuki⁷,

Affiliation:

1. Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Japan

2. Department of Hepatology, Aso Iizuka Hospital, Japan

3. Department of Hepatology, Steel Memorial Yawata Hospital, Japan

4. Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Japan

5. Department of Internal Medicine, Fukuoka City Hospital, Japan

6. Department of Gastroenterology, Chihaya Hospital, Japan

7. Department of Medicine and Bioregulatory Science, Kyushu University, Japan

8. Department of Gastroenterology and Hepatology, Fukuokahigashi Medical Center, Japan

9. Department of Center for Liver Disease, Kokura Medical Center, Japan

10. Department of Internal Medicine, Social Insurance Nakabaru Hospital, Japan

11. Department of Gastroenterology, Kyushu Rosai Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/61/21/61_9237-21/_pdf

Reference24 articles.

1. 1. Villanueva A. Hepatocellular carcinoma. N Engl J Med 380: 1450-1462, 2019.

2. 2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.

3. 3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.

4. 4. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20: 282-296, 2019.

5. 5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma;Hepatology Research;2023-11-04

2. Ramucirumab;Reactions Weekly;2023-06-10